Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.

Rezvani K, Barrett AJ.

Best Pract Res Clin Haematol. 2008 Sep;21(3):437-53. doi: 10.1016/j.beha.2008.07.004. Review.

2.

T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation.

Schetelig J, Kiani A, Schmitz M, Ehninger G, Bornhäuser M.

Cancer Immunol Immunother. 2005 Nov;54(11):1043-58. Epub 2005 May 11. Review.

PMID:
15887014
3.

Posttransplantation vaccination: concepts today and on the horizon.

Rezvani K.

Hematology Am Soc Hematol Educ Program. 2011;2011:299-304. doi: 10.1182/asheducation-2011.1.299. Review.

PMID:
22160049
4.

[Target antigens for graft-versus-host disease (GVHD) and graft-versus-leukemia/tumor (GVL/T)].

Tanaka J.

Nihon Rinsho. 2003 Sep;61(9):1512-9. Review. Japanese.

PMID:
14515717
5.

Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.

Barrett AJ, Rezvani K.

Clin Exp Immunol. 2007 May;148(2):189-98. Review.

6.

Minor histocompatibility antigens--targets of graft versus leukemia responses.

Riddell SR, Murata M, Bryant S, Warren EH.

Int J Hematol. 2002 Aug;76 Suppl 2:155-61. Review.

PMID:
12430918
7.

CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.

Matte-Martone C, Liu J, Jain D, McNiff J, Shlomchik WD.

Blood. 2008 Apr 1;111(7):3884-92. doi: 10.1182/blood-2007-11-125294. Epub 2008 Jan 25.

8.

Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.

Spierings E, Kim YH, Hendriks M, Borst E, Sergeant R, Canossi A, Oudshoorn M, Loiseau P, Dolstra H, Markiewicz M, Leffell MS, Pereira N, Kircher B, Turpeinen H, Eliaou JF, Gervais T, Laurin D, Enczmann J, Martinetti M, Thomson J, Oguz F, Santarone S, Partanen J, Siekiera U, Alessandrino EP, Kalayoglu S, Brand R, Goulmy E.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1244-53. doi: 10.1016/j.bbmt.2013.06.001. Epub 2013 Jun 10.

9.

Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.

Falkenburg JH, Marijt WA, Heemskerk MH, Willemze R.

Curr Opin Hematol. 2002 Nov;9(6):497-502. Review.

PMID:
12394171
10.

New developments in allotransplant immunology.

Barrett AJ, Rezvani K, Solomon S, Dickinson AM, Wang XN, Stark G, Cullup H, Jarvis M, Middleton PG, Chao N.

Hematology Am Soc Hematol Educ Program. 2003:350-71. Review.

PMID:
14633790
11.

High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.

Young FM, Campbell A, Emo KL, Jansson J, Wang PY, Jordan CT, Mullen CA.

Biol Blood Marrow Transplant. 2008 Jun;14(6):622-30. doi: 10.1016/j.bbmt.2008.02.015. Epub 2008 Apr 14.

12.

[Antigen-specific allogeneic immunotherapy--selective augmentation of GVL effects].

Akatsuka Y.

Gan To Kagaku Ryoho. 2008 May;35(5):713-9. Review. Japanese.

PMID:
18487905
13.

Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.

van der Zouwen B, Kruisselbrink AB, Frederik Falkenburg JH, Jedema I.

Biol Blood Marrow Transplant. 2014 Jun;20(6):760-9. doi: 10.1016/j.bbmt.2014.03.002. Epub 2014 Mar 7.

14.

Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.

van Bergen CA, van Luxemburg-Heijs SA, de Wreede LC, Eefting M, von dem Borne PA, van Balen P, Heemskerk MH, Mulder A, Claas FH, Navarrete MA, Honders WM, Rutten CE, Veelken H, Jedema I, Halkes CJ, Griffioen M, Falkenburg JH.

J Clin Invest. 2017 Feb 1;127(2):517-529. doi: 10.1172/JCI86175. Epub 2017 Jan 9.

15.

[Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].

Hudecek M, Bartsch K, Tschiedel S, Niederwieser D.

Dtsch Med Wochenschr. 2008 Jul;133(28-29):1511-6. doi: 10.1055/s-2008-1081100. Review. German.

PMID:
18597211
16.

Relationship between graft-versus-host disease and graft-versus-leukaemia in partial T cell-depleted bone marrow transplantation.

van der Straaten HM, Fijnheer R, Dekker AW, Nieuwenhuis HK, Verdonck LF.

Br J Haematol. 2001 Jul;114(1):31-5.

PMID:
11472341
17.

Understanding and harnessing the graft-versus-leukaemia effect.

Barrett AJ.

Br J Haematol. 2008 Sep;142(6):877-88. doi: 10.1111/j.1365-2141.2008.07260.x. Epub 2008 Jun 28. Review.

PMID:
18564358
18.

Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.

Stevanović S, Nijmeijer BA, van Schie ML, Salvatori DC, Maas S, Griffioen M, Falkenburg JH.

Biol Blood Marrow Transplant. 2013 Jun;19(6):867-75. doi: 10.1016/j.bbmt.2013.03.003. Epub 2013 Mar 13.

19.

Minor histocompatibility antigens in human stem cell transplantation.

Falkenburg JH, van de Corput L, Marijt EW, Willemze R.

Exp Hematol. 2003 Sep;31(9):743-51. Review.

PMID:
12962719
20.

Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.

Lu YF, Gavrilescu LC, Betancur M, Lazarides K, Klingemann H, Van Etten RA.

Blood. 2012 Jan 5;119(1):273-84. doi: 10.1182/blood-2011-01-331009. Epub 2011 Nov 9.

Supplemental Content

Support Center